Article: Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.

Full Text (publisher's website) ; Article Metadata ; Article Data (extracted)
Gleason RL; Caulk AW; Seifu D; Parker I; Vidakovic B; Getenet H; Assefa G; Amogne W
PLoS ONE, 2015

10.1371/journal.pone.0117125.t001

Table 1 Baseline characteristics, body composition.

End-point	HIV-Negative	HAART Naïve	Efavirenz (EFV)	Nevarapine (NVP)	Lopinavir/r (LPV/r)
	(n=36)	(n=51)	(n=91)	(n=95)	(n=44)
Demographics
Age (yrs)	39(29-45)	38(32-45)	38(34-45)	37(32-42)	39(35-44)
Male ratio [# (%)]	8 (22%)	14(27%)	23 (25%)	21(22%)	14 (32%)
HIV / HAART History
CD4+ count	730(656-1047)	395(182-546)^A	349(232-481)^A	390(271-534)^A	285(147-453)^A,e
Viral Load (log10copies/mL)	--	3.6(2.2-4.7)	<1.6(<1.6-<1.6)^B	<1.6(<1.6-<1.6)^B	<1.6(<1.6-<1.6)^B
Viral Load (% BDL)	--	18%	92%B	87%^B	81%^B
Yrs since diagnosis	--	1.6(0.3-3.7)	5.7(3.4-7.0)^B	6.0(5.6-7.4)^B,d	6.5(5.3-8.3)^B,d
Yrs on HAART	--	--	5.0(3.2-6.2)	5.7(3.9-6.2)	5.9(4.2-6.8)^d
Yrs on Current Regimen	--	--	2.5(1.5-4.4)	3.8(1.9-5.7)^d	1.8(0.7-3.2)^E
Current NRTI backbone
TDF+3TC [# (%)]	--	--	55(60%)	38(40%)	28(64%)
AZT+3TC [# (%)]	--	--	35(38%)	53(56%)	7(16%)^E
Other [# (%)]	--	--	1(1%)	4(4%)^e	9(20%)
Previous Regimen
All [# (%)]	--	--	39(43%)	29(31%)	40(91%)^D,E
EFV-containing [# (%)]	--	--	24(26%)	5(5%)	20(45%)^d,e
NVP-containing [# (%)]	--	--	15(16%)	24(25%)	22(50%)^d,e
Body Composition
BMI [kg/m2]	22(20-26)	22(20-26)	21(19-24)	23(20-25)	22(18-25)
WHR [ ]	0.82(0.77-0.86)	0.84(0.79-0.89)	0.86(0.81-0.91)^A	0.86(0.81-0.92)^A	0.88(0.82-1)^A,b
Skinfold Thickness
Tricep [mm]	12.2(7.6-15.3)	10.8(5.4-14.9)^A	6.7(3.9-9.5)^A,B	6.7(4.2-10.0)^A,b	8.0(5.2-10.6)^A
Bicep [mm]	6.1(3.3-8.8)	6.2(3.1-9.2)	3.1(2.4-5.8)^A,B	3.5(2.4-6.0)^A,B	4.4(2.7-8.1)
Suprailiac [mm]	9.3(6.4-13.7)	7.9(5.0-13.1)	6.2(4.0-8.9)^A,b	7.4(4.3-10.9)^A	7.7(4.0-12.4)
Sub-scapula [mm]	20.9(16.0-27.1)	19.8(11.7-28.4)	15.8(9.9-20.7)^a,b	18.4(11.2-28.2)^d	20.2(9.8-30.4)^d
Trunk:arm [ ]	1.6(1.4-2.0)	1.8(1.4-2.2)	2.1(1.4-2.8)^a,b	2.2(1.5-3.3)^a,b	2.1(1.5-2.6)^a,b
Observed change in fat (% observing decrease in fat / % observing increase in fat
Face [%]	0%/0%	8%/4%	27%^A,b/5%	15%^A/23%^A,b,d	36%^A,b/11%
Arms [%]	0%/0%	4%/4%	16%^A/4%	8%/13%^A	23%^A/7%
Legs [%]	0%/0%	6%/2%	22%^A/5%	17%^A/20%^A,b	25%/7%
Abdomen [%]	0%/0%	4%/6%	1%/32%^A,B	1%/29%^A,B	2%/41%^A,B
Chest [%]	0%/0%	4%/0%	2%/11%^a,b	1%/9%^a,b	0%/25%^a,b
Buffalo hump [%]	0%/0%	4%/0%	1%/7%	0%/9%^a,b	2%/14%
Neck [%]	0%/0%	4%/0%	3%/5%	0%/8%	2%/16%
Body [%]	0%/8%	20%^a/14%	14%^A/32%^a	13%^a/42%^A,B	16%/36%

Continuous variables are reported as median (interquartile range). BMI = body mass index, and WHR = waist-to-hip ratio, mm = millimeters.

A, a = p<0.005 or p<0.05 versus HIV-negative controls, respectively;

B, b = p<0.005 or p<0.05 versus HAART-naive, respectively;

D, d = p<0.005 or p<0.05 versus EFV, respectively;

E, e = p<0.005 or p<0.05 versus NVP, respectively.

Report miscurated data

Inferred neuron-electrophysiology data values

Neuron Type	Neuron Description	Ephys Prop	Extracted Value	Standardized Value	Content Source